Global healthcare platform CureMeAbroad has raised $1.1 million to expand its cross-border medical-tourism operations, as reported in October 2026.
The startup operates in the fast-growing medical value travel segment, connecting international patients with hospitals and treatment options — a space where India has natural advantages in cost, clinical quality and English-language care.
Medical tourism is having a moment: with elective procedures in the US and Europe carrying long wait times and steep bills, platforms that package treatment, travel and recovery into a trusted experience are seeing real demand. CureMeAbroad's raise suggests investors see room for a tech-led aggregator to organise this fragmented market.
Details of the round's investors were not disclosed in the announcement. The company plans to deploy the capital toward platform expansion and scaling its global patient acquisition.
Why it matters for founders
Medical value travel is one of India's most underrated export industries. If you're building in healthtech, the cross-border patient opportunity — treatment plus travel plus trust — is wide open for a brand that can guarantee quality end-to-end. CureMeAbroad's raise is an early signal of investor appetite here.